E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Sub-optimally controlled moderate to severe asthma and symptoms of GERD. |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 6.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10003553 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To compare the anti-asthmatic effect of esomeprazole, given either as 40 mg twice daily or 40 mg once daily, with that of placebo in adult patients with moderate to severe asthma and symptoms of gastroesophageal reflux disease GERD by evaluation of change in morning Peak Expiratory Flow mPEF from baseline mean of the last 7 days in the run-in period to treatment period mean of all available data during the treatment period as the primary outcome variable. |
|
E.2.2 | Secondary objectives of the trial |
- To investigate the effect on symptoms of GERD when treating adult patients having moderate to severe asthma and symptoms of GERD with esomeprazole 40 mg twice daily or 40 mg once daily or placebo by evaluation of change in symptoms of GERD as measured by Reflux Disease Questionnaire RDQ - To assess the safety and tolerability of the treatments esomeprazole 40 mg twice daily and 40 mg once daily for 6 months. |
|
E.2.3 | Trial contains a sub-study | Information not present in EudraCT |
E.3 | Principal inclusion criteria |
1. Provision of written informed consent. 2. Female or male aged 18 to 70 years inclusive. 3. Clinical diagnosis of asthma as defined by the ATS definition Expert Panel Report 2 1997 for at least 6 months prior to Visit 2. 4. A reversibility in FEV1 of at least 12 and 8805;0.20 L from baseline after inhalation of 2 x 0.5 mg terbutaline Bricanyl Turbuhaler or 2 x 0.2 mg albuterol via a pressurized metered dose inhaler pMDI . 5. Daily use of inhaled GCS and LABA for 8805;3 months prior to Visit 2. 6. A history of at least one clinically important asthma exacerbation, as judged by the investigator, between 1 to 12 months prior to Visit 2 ie, not within the last 30 days prior to Visit 2 . 7. A history of at least 3 months of 1 or more of the 3 GERD symptoms listed in inclusion criterion no 8. 8. Symptoms or history of GERD. According to scores in patient s self-reported RDQ at least 1 of the following GERD symptoms must have a frequency of 8805; 2 days during the last week and at least 1 symptom must be of at least moderate severity -a burning feeling behind the breastbone -pain behind the breastbone -an acid taste in the mouth or -patient must have a documented history of an abnormal esophageal 24-hour pH monitoring up to 3 years prior to Visit 2, measured by catheter based or catheter free BRAVO techniques according to the manufacturer s instruction. The limit of percentage esophageal acid exposure, should be the same as the local references for respective technique. |
|
E.4 | Principal exclusion criteria |
1. Patients with clinically relevant abnormalities at Visit 2 ECG, vital signs, physical examination, or laboratory values , as judged by the investigator. 2. Any significant disease or disorder eg, cardiovascular, pulmonary other than asthma , gastrointestinal other than GERD , liver, renal, neurological, musculoskeletal, endocrine, metabolic, malignant, psychiatric, major physical impairment which, in the opinion of the investigator, may either put the patient at risk because of participation in the study, or may influence the results of the study or patient s ability to participate in the study. 3. Patients with alarm symptoms such as unintentional weight loss, haematemesis, jaundice, dysphagia, or any other sign indicating serious or malignant disease. 4. Patients with a smoking history of 8805;10 pack-year ie, equivalent of smoking 20 cigarettes per day for 10 years . 5. Use of oral, rectal, or parenteral GCS within 30 days prior to Visit 2. 6. Patients 50 years of age with GERD symptoms according to inclusion criterion no 8 who have not been investigated x-ray of upper gastrointestinal tract or endoscopy within 1 year prior to Visit 2 to exclude upper gastrointestinal tract malignant disease. 7. Patients who have had previous surgery on the esophagus or the stomach. 8. Patients with endoscopy-verified erosive esophagitis within the last 16 weeks prior to Visit 2 or Barrett s esophagus with associated dysplasia. 9. Pregnancy or breast-feeding. Fertile women without acceptable contraceptive measures, as judged by the investigator. Fertile women are defined as women of child-bearing potential from first menstruation to 1 year after last menstruation. Acceptable methods of birth control include contraceptive patch, intrauterine device, implantable progesterone device, progesterone intramuscular injection, oral contraceptive started at least 1 month prior to Visit 2 and continuing for the duration of the study , or condoms with spermicide, tubal ligation, and double-barrier methods. Single-barrier methods alone and rhythm methods are not acceptable methods of birth control. 10. Patients with a known hypersensitivity to any component of any PPI esomeprazole,omeprazole,lansoprazole, rabeprazole, pantoprazole, or tenatoprazole. 11. Planned donation of blood during the study. 12. Planned hospitalisation during the study. 13. Suspected poor capability, as judged by the investigator, of following instructions of the study, eg, because of alcohol or drug abuse, or any other reason. 14. Participation in another clinical study of any investigational drug within 30 days prior to Visit 2 or during the study. 15. Previous randomization in the present study. 16. Involvement in the planning and conduct of the study applies to both AstraZeneca staff and staff at the study site . |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Efficacy Primary outcome variable Change in mPEF from baseline mean of the last 7 days during the run-in period to treatment period mean of all available data during the treatment period . |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | Information not present in EudraCT |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | Yes |
E.6.13 | Others | Information not present in EudraCT |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 1 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 1 |